Viridian Therapeutics Inc 's ROA from the first quarter of 2026 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Viridian Therapeutics Inc 's ROA in the first quarter of 2026?
Viridian Therapeutics Inc recorded a cumulative net loss of $-371 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -50.7%.

However, within the Healthcare sector 568 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 3936, from total ROA ranking in the fourth quarter of 2025 at 4571.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	6.52 %	16.86 %	-1.56 %	4.86 %	51.12 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-371	-346	-278	-308	-270
Return On Assets (TTM)	-50.7 %	-48.05 %	-40.46 %	-44.74 %	-39.61 %
VRDN's Total Ranking	# 3936	# 4571	# 3907	#	# 4078
Total Assets (TTM) in million	789	899	576	661	741
Seq. Total Assets Change	-12.27 %	56.14 %	-12.85 %	-10.76 %	-3.76 %
Seq. Net Income Change	-	-	-	-	-

VRDN's 5 Years Annual ROA >> Back to VRDN Management Effectiveness >> Compare VRDN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 33
Sector	# 569
Overall	# 3902

Return On Assets Statistics
High	Average	Low
-39.55 %	-47.5 %	-61.06 %
(Dec 31 2024)		(Dec 31 2023)

Financial Statements
Viridian Therapeutics Inc 's Assets	$ 789 million	VRDN's Balance sheet
Viridian Therapeutics Inc 's Income	$ -105 million	Quarterly VRDN's Income Statement
VRDN's Income by Division		See VRDN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	21.43 %	51.12 %	12.81 %	114.53 %	54.31 %
Total Assets in million	899	741	490	434	203
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-343	-270	-238	-130	-79
Annual Return On Assets	-38.09 %	-36.45 %	-48.5 %	-29.89 %	-39.21 %

VRDN's 5 Years Annual ROA >> Back to VRDN Management Effectiveness >> Compare VRDN ROA to its Competitors

More Return On Assets Ratios
VRDN's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VRDN's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VRDN's Competitors
Subscribers only: Roa for Viridian Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for VRDN's Customers

You may also want to know
VRDN's Roi	VRDN's Inventory Turnover Ratio	VRDN's Growth Rates	VRDN's Dividend Comparisons
	VRDN's Profitability Ratios	VRDN's Asset Turnover Ratio	VRDN's Dividend Growth
VRDN's Roe	VRDN's Valuation Ratios	VRDN's Financial Strength Ratios	VRDN's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.